Use of probiotics in the prevention and treatment of cancer, and in particular for colorectal cancer
The strain of Lactobacillus brevis was isolated from pulque (alcoholic drink of Mexican origin).
Context
This strain (LBH1073) is able to stop cell proliferation on intestinal epithelial human cells (HT-29, HTC116 and Caco-2) and on other epithelial cells (like TC-1 from pulmonary epithelial cells of mouse) at a comparable level of 5-fluoro-uracile (5-FU: anti-cancer drug used as a positive control in the experiments).
Advantages
QPS strain - Team expertise in micobiota and interaction between microorganisms and host
Applications
The idea is not to replace present treatments but to complement these treatments with probiotics. This association can improve treatment efficiency, decrease the side effects or solve the problem of antibiotic-resistant cells. It has been illustrated in three articles published in Science (Sivan et al., 2015; Vetizou et al., 2015; Gopalakrishnan et al., 2018; Routy et al., 2018).
See other transfer opportunities on the INRA Transfert website
Type of expected transfer
Licence option with R&D programme or licence
TRL Sclae: 3
Development level
The next step of this project is to validate the anti-tumoral effects of this strain Lactobacillus brevis LBH1073 in vivo and then to carry out a clinical pilot study.
